CDRH Offers Primer On Its Guidance Priority-Setting Process
This article was originally published in The Gray Sheet
Executive Summary
The device center’s priorities for guidance development shift throughout the year based on evolving urgencies and mandates, and are not fully reflected on the public website. CDRH described its process at a meeting this month, and heard guidance wish lists for industry and other stakeholders.
You may also be interested in...
Draft Guidance Docs Should Be Transitory, Industry Insists
Device industry advocates stressed to CDRH during a meeting last week that draft-guidance documents need to more routinely be finalized or withdrawn in an expedited manner, and that agency staffers must resist using the out-for-comment document as if they are settled policy.
Minute Insight: Enovis Buys Lima To Great Billion-Dollar Recon Business
Enovis has agreed to buy Italian orthopedic implant manufacturer Lima from a private equity firm for €800m – about $845m. The deal will expand Enovis’ presence in the fast-growing international extremities market and improve its manufacturing and innovation facilities.
Contingency Planning: Guidance Doc Details Handling Clinical Trials During Emergencies
The agency urges sponsors to keep patient safety “first and foremost” in determining how to continue a clinical trial during a natural disaster, public health emergency, or other crisis.